$XRTX News

XORTX Therapeutics (XRTX) Stock Jumps Over 22% After Hours: Here's Why

XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout

XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity

XORTX Outlines Anticipated FDA IND Submission For XRx-026 Gout Program

XORTX Therapeutics (XRTX) Stock Climbs 16% After Hours: Here's What You Need to Know

XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™

XORTX Therapeutics Starts Production Of Drug, Tablet Manufacturing For Its XRx-026 Trial To Treat Gout

XORTX Re-Engages Investor Relations Program

XORTX Announces Termination and Postponement of Investor Relations Program

XORTX Therapeutics Terminates And Postpones Investor Relations And Marketing Agreement With IR Agency

XORTX Announces Director Resignation

XORTX Appoints New Director

XORTX Therapeutics Appoints Mika Grasso as Co-CEO; Voluntarily Delisting from the TSX Venture Exchange

XORTX Provides Corporate Update and Announces Appointment of Mika Grasso as Co-CEO

XORTX Therapeutics Appoints Mika Grasso Co-CEO

XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange

XORTX Announces Closing of US$5 Million Public Offering

E.F. Hutton & Co. Serves as Exclusive Placement Agent on XORTX Therapeutics Inc. $5 Million Public Offering

XORTX Announces US$5 Million Public Offering

XORTX Meets Nasdaq Continued Listing Requirements